Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author
|
|
- Gabriel Simmons
- 8 years ago
- Views:
Transcription
1 Version History Policy Title Drugs for MS.Drug facts box fampridine Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required by local organisations) Previous Versions Version Date Changes 1
2 Drugs for multiple sclerosis Summaries of key information and evidence for efficacy and safety January 2013 Drug Facts Box for Fampridine-SR What is this drug for? 1 Improvement of walking in adult patients with multiple sclerosis Who is this drug for? 1 Adults with multiple sclerosis and a walking disability score of 4 to 7 on the EDSS (Expanded Disability Status Scale) Patients under age 18 Who should not be taking this drug? 1 Patients with any severity of renal disease Patients with prior history or current presentation of seizure How is this drug administered? 1 Prolonged-release tablet What dose of this One 10 mg tablet drug is administered? 1 How often is this drug Twice daily (for two weeks, then need should be reassessed) administered? 1 What is the cost of One 28-tablet pack, sufficient for one patient for two weeks, costs 181 this drug? What are the adverse Most commonly: seizure, insomnia, anxiety, balance disorder, dizziness, reactions associated paraesthesia, tremor, headache, asthenia and urinary tract infection with this drug? Licensing timeline Launched in the UK in July 2011 Other information: 1 Fampridine-SR should be given with caution to patients with cardiac rhythm or conduction disorders Studies Summary of methods Three double-blind, placebo-controlled, RCTs evaluated the efficacy of fampridine-sr as a treatment to improve walking speed in patients with MS. 2,3,4 One trial was a phase 2 trial, assessed fampridine- SR at doses of 10, 15 or 20 mg twice daily [15 and 20 mg doses are unlicensed]; the other trials were phase 3 trials that assessed fampridine-sr 10 mg twice daily. Included patients had MS in a stable phase with an average EDSS of 5.8 and were able to complete two, 25-foot timed walk tests. Following screening and a two-week placebo run-in period, the double-blind treatment phase lasted 9 to 14 weeks, with two to four weeks follow up. Patients were given 25-foot timed walk tests before, during and after treatment. The primary outcome measure in two trials was the number of patients who showed a response to treatment, defined as a faster walking speed for at least three of four 25- foot timed walk tests whilst on treatment compared with off-treatment periods. In the third trial, the primary outcome was the percentage change in walking speed. In this trial, response to treatment was measured in a post-hoc analysis. Other outcome measures across the trials were the 12-item multiple sclerosis walking scale (MSWS-12), the Ashworth score for spasticity, the lower extremity manual muscle test (LEMMT), and the subject s and clinician s global impression of change. Quality of the trials The design of the trials was fairly good, all three being double-blind, randomised and placebo controlled. However, the trials were marred by reporting most of the secondary outcomes in terms of responders and non-responders, which implied that efficacy was greater than from the actual results in the fampridine-treated versus the placebo-treated patients (these results are not included below). Main results In all three trials, significantly more fampridine-sr-treated patients showed a response to treatment than those receiving placebo (35 to 43% vs. 9%, p < 0.05). The improvement in mean walking speed 2
3 from baseline was significantly greater with fampridine treatment than with placebo in two trials (p < 0.05). However, the improvements in mean walking speeds seen in the trials were not very large: 0.09 to 0.3 feet/second in fampridine-treated patients and 0.04 to 0.18 feet/second in placebo-treated patients. Adverse events The adverse events seen in the trials are described above. References 1. Biogen Idec Ltd. Fampyra 10 mg prolonged-release tablets. EMC <accessed 3/2012> 2. Goodman AD, Brown TR, Cohen JA et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71: Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373: Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68: Fampyra Assessment Report (EMEA/H/C/002097). European Medicines Agency _Public_assessment_report/human/002097/WC pdf <accessed 4/2012> 3
4 Table 1. Fampridine: study design Study (n randomised) MS-F202 (Goodman et al., ) Multicentre (24) n = 206 Jadad: 3 Funding: not stated but some authors were employees of the manufacturer MS-F203 (Goodman et al., ) Multicentre (33) n = 300 Jadad: 5 Company sponsored Funding: university Inclusion criteria Exclusion criteria Duration of study Treatment arms All doses given twice daily Adults, aged 18 to 70 Clinically defined multiple sclerosis Able to complete two trials of the timed 25-foot walk test (T25FW) in an average time of 8 to 60 seconds at screening Adults, aged 18 to 70 Clinically defined multiple sclerosis Able to complete two trials of the T25FW in an average time of 8 to 45 seconds at screening Recent MS relapse Recent change in medication Onset of MS exacerbation within 60 days of screening History of seizures or evidence of epileptiform activity on EEG Any condition that would interfere with study conduct 2-week titration for higher doses groups, 12-week stable dose treatment period, 2-week follow up 14 weeks double-blind treatment, 4-week follow up (52) Fampridine-SR 15 mg (50) Fampridine-SR 20 mg (57) Placebo (47) (228) Placebo (72) Main outcomes Primary Secondary Percentage change in walking speed during treatment relative to baseline using T25FW LEMMT Ashworth score for spasticity Patient and clinician global impression of change MSQLI MSWS-12 Other multiple sclerosis functional composite components Response to treatment (faster walking speed in 3 of 4 assessment visits on treatment, compared with maximum speed assessed when not treated) 12-item multiple sclerosis walking scale Patient and clinician global impression of change Ashworth score (average of three muscle groups) LEMMT (measured strength in four muscle groups) MSWS-12 4
5 MS-F204 (Goodman et al., ) Multicentre (39) n = 239 Jadad: 4 As for MS-F203 above As for MS-F203 above 9 weeks double-blind treatment, 4-week follow up (120) Placebo (119) As for MS-F203 above Funding: company EEG, electroencephalogram; MS, multiple sclerosis; MSQLI, Multiple Sclerosis Quality of Life Inventory; MSWS-12, Multiple Sclerosis Walking Scale; RCT, randomised controlled trial; SD, standard deviation; T25FW, timed 25-foot walk test Fampridine Table 2. Results (data taken from published articles with supplementary material from EMA assessment report for fampridine 5 ) Outcomes: Primary outcomes Secondary outcomes Placebo MS-F202 2 (n = 206) MS-F203 3 (n = 300) MS-F204 4 (n = 239) Fampridine-SR 10 mg Percentage of patients who responded to 8.5% 35.3% 8% treatment 2-4 Average change in walking speed from baseline in ft./second ± SE 5 (baseline speed) 0.04 ± (1.8) 0.09 ± (1.83) Placebo Placebo 0.11 ± (2.04) 35%*** OR 4.75 (2.08 to 10.86) 0.3 ± 0.040* (2.02) 9% 0.18 ± (2.21) 43%*** OR 8.14 (3.73 to 17.74) 0.31 ± 0.046* (2.12) Average change in MSWS- 12 ± SD ± ± ± ± ± ± 1.20* Change in LEMMT ** * * p < 0.05 vs. placebo, ** p < vs. placebo; *** p < vs. placebo; significant difference reported but no p value quoted; CI, confidence interval; ft./s, feet per second; LEMMT, lower extremity manual muscle test; OR, odds ratio; MSWS-12, Multiple sclerosis walking scale; SD, standard deviation; SE, standard error of the mean 5
Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationVersion History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b
Version History Policy Title Drugs for MS.Drug facts box Interferon beta 1b for secondary progressive MS (SPMS) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationFampridine (Fampyra ) in multiple sclerosis
Fampridine (Fampyra ) in multiple sclerosis NHS Regional Drug & Therapeutics Centre (Newcastle) March 2012 Summary Fampridine is a first-in-class oral potassium channel blocker licensed to improve walking
More informationAMPYRA (dalfampridine) Important Safety Information
NEWS RELEASE Acorda to Present New rhigm22 and AMPYRA (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 10/7/2015 ARDSLEY, N.Y.--(BUSINESS
More informationSummary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationRAPID COMMUNICATION. A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis
RAPID COMMUNICATION A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis Andrew D. Goodman, MD, 1 Theodore R. Brown, MD, MPH, 2 Keith R. Edwards, MD, 3 Lauren B. Krupp, MD, 4 Randall
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationThe submission positioned dimethyl fumarate as a first-line treatment option.
Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an
More informationCost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness
More informationMultiple Sclerosis (MS) Class Update
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Multiple Sclerosis (MS) Class Update Month/Year of
More informationTAKING THE NEXT STEP
FOR ADULTS WITH MS TAKING THE NEXT STEP AMPYRA TREATMENT GUIDE walking better matters See the Patient Medication Guide below. About AMPYRA (dalfampridine) Extended release tablets How is AMPYRA different?
More informationCost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide
More informationTHE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THAT S WHEN I ASKED FOR THE WALKING PILL
THE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THAT S WHEN I ASKED FOR THE WALKING PILL See page 12 for FREE* TRIAL OFFER *Limitations and restrictions apply. Actor portrayal AMPYRA (dalfampridine)
More informationDimethyl fumarate for treating relapsing remitting multiple sclerosis
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Dimethyl fumarate for treating relapsing remitting multiple sclerosis This guidance was developed using the single technology
More informationMultiple Sclerosis - Relapsing and Remissioning
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationDimethyl fumarate for treating relapsing-remitting multiple sclerosis
Dimethyl fumarate for treating relapsing-remitting multiple Issued: August 2014 guidance.nice.org.uk/ta320 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationConflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011
Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationPeninsula Health Technology Commissioning Group
Peninsula Health Technology Commissioning Group Health Technology Assessment and Commissioning Decision Sativex for treatment of spasticity in multiple sclerosis Clinical case: Generally supportable Cost-effectiveness
More information2. Background This drug had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July 2009 1. Purpose of Application The submission
More information1. Comparative effectiveness of alemtuzumab
Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued
More informationNew and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents
New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Giovannoni G, Gold R, Selmaj K, et al,
More informationTreatment of walking impairment in multiple sclerosis with dalfampridine
Therapeutic Advances in Neurological Disorders Review Treatment of walking impairment in multiple sclerosis with dalfampridine Andrew R. Blight Ther Adv Neurol Disord (2011) 4(2) 99 109 DOI: 10.1177/ 1756285611403960!
More informationTwo-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple
More informationfingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK
fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK 08 August 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationU.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
More informationIssues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
More informationteriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd.
teriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd. 10 January 2014 (Issued 07 February 2014) The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More information2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
More informationEconomic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or
Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated Summary In January 2007 Biogen Idec
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationStudy Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch
BLA: STN 103471 Betaseron (Interferon β-1b) for the treatment of secondary progressive multiple sclerosis. Submission dated June 29, 1998. Chiron Corp. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D.
More informationMedication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014
Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective
More informationTeriflunomide for treating relapsing remitting multiple sclerosis
Teriflunomide for treating relapsing remitting multiple Issued: January 2014 last modified: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationpeginterferon 63, 94 and 125 microgram solution for injection in pre-filled syringe (Plegridy ) SMC No. (1018/14) Biogen Idec Ltd.
peginterferon 63, 94 and 125 microgram solution for injection in pre-filled syringe (Plegridy ) SMC No. (1018/14) Biogen Idec Ltd. 05 December 2014 The Scottish Medicines Consortium (SMC) has completed
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationAlemtuzumab for treating relapsing-remitting multiple sclerosis
Alemtuzumab for treating relapsing-remitting multiple Issued: May 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationNew Therapies in MS: Filling up the spaces. Eli Silber Consultant Neurologist Kings College Hospital
New Therapies in MS: Filling up the spaces Eli Silber Consultant Neurologist Kings College Hospital What is wrong with the current therapies? The current therapies have limited efficacy 1 st line relapse
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationfingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd
fingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationNalmefene for reducing alcohol consumption in people with alcohol dependence
Nalmefene for reducing alcohol consumption in people with alcohol dependence Issued: November 2014 guidance.nice.org.uk/ta325 NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationManaging Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
More informationLiterature Scan: Oral Multiple Sclerosis Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C
FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor
More informationPatients with confirmed relapse 111 26 (23.4 %) 104 16 (15.4 %) 1.52 [0.87; 2.67] p = 0.143 Probability of a relapse by week 96
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationBEST in MH clinical question-answering service
Best Evidence Summaries of Topics in Mental Healthcare BEST in MH clinical question-answering service Question In people with PTSD (including single and multiple event trauma) how effective is prazosin
More informationSummary of the risk management plan (RMP) for Cerdelga (eliglustat)
EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to
More informationSupplementary Online Content
Supplementary Online Content Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationA New MS Consortium for A New MS Clinical Outcome Measure
A New MS Consortium for A New MS Clinical Outcome Measure Nicholas G. LaRocca, Ph.D. Richard Rudick, M.D. Lynn Hudson, Ph.D. Co-Directors, MSOAC American Academy of Neurology March 20 th, 2013 The problem
More informationRivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Issued: May 2012 guidance.nice.org.uk/ta256 NICE has accredited the process used by the Centre for Health
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More information- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -
PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with
More informationTreatment guidelines for relapsing MS and the two step approach for disease modifying therapy
Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health
More informationBEST in MH clinical question-answering service
Best Evidence Summaries of Topics in Mental Healthcare BEST in MH clinical question-answering service Question In adults with a diagnosis of psychotic / delusional depression how effective is electroconvulsive
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta367
Vortioxetine for treating major depressive e episodes Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta367 NICE 2015. All rights reserved. Contents 1 Guidance... 3 2 The
More informationTalking to Your Doctor Discussion Guide
My Responses to the Discussion Guide In the past two weeks: 1. How much has MS limited your ability to walk? 2. How much has MS limited your ability to run? 3. How much has MS limited your ability to climb
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationLaquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
More informationBiotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015
Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 1 Timo Veromaa President & CEO 2 Company Highlights 2014 through Q1 2015 Continued advances
More informationStage A & C Sample Data Collection Form
Stage A & C Sample Data Collection Form Instructions: Review a minimum of 20 patient charts (or another number determined to be appropriate) from patients most recently admitted, and complete this Data
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511351:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: CR002353 Johnson & Johnson Pharmaceutical
More informationNew perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
More informationNews on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS
News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active
More informationrifaximin 550mg film-coated tablets (Targaxan ) SMC No. (893/13) Norgine Pharmaceuticals Ltd
rifaximin 550mg film-coated tablets (Targaxan ) SMC No. (893/13) Norgine Pharmaceuticals Ltd 09 August 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationAntidepressants and suicidal thoughts and behaviour. Pharmacovigilance Working Party. January 2008
Antidepressants and suicidal thoughts and behaviour Pharmacovigilance Working Party January 2008 PhVWP PAR January 2008 Page 1/15 1. Introduction The Pharmacovigilance Working Party has on a number of
More informationEfficacy and safety of modafinil (Provigil ) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
179 PAPER Efficacy and safety of modafinil (Provigil ) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study K W Rammohan, J H Rosenberg, D J Lynn, A M Blumenfeld, C P Pollak,
More informationNatalizumab for the treatment of adults with highly active relapsing remitting multiple sclerosis
Natalizumab for the treatment of adults with highly active relapsing remitting multiple sclerosis Premeeting briefing This briefing presents major issues arising from the manufacturer s submission, Evidence
More informationImmunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020
Page 020 4.0 Efficacy of Mitoxantrone in Multiple Sclerosis The efficacy of mitoxantrone in MS was demonstrated in two well-designed, randomized trials: Studies 901 and 902. The study design and efficacy
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationCannabis. Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353
Cannabis Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Cannabis Date of issue: June 2010 Review date: June 2011 Contents 1. Introduction 1 2. Background
More informationTeriflunomide (Aubagio)
Teriflunomide (Aubagio) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would like to speak
More informationJ.P. Morgan Cazenove Therapeutic Seminar
Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report
Suffolk PCT Drug & Therapeutics Committee New Medicine Report This drug has been reviewed because it is a product that may be prescribed in primary care. Medicine Fesoterodine (Toviaz, Pfizer) Document
More informationProduct: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More informationMedia Release. Basel, 8 October 2015
Media Release Basel, 8 October 2015 Roche s ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis Ocrelizumab
More informationA Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
european urology 54 (2008) 740 764 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology A Systematic Review and Meta-Analysis of Randomized Controlled Trials
More informationEvidence Review Group Report commissioned by the NIHR HTA Programme on behalf of NICE. Omalizumab for previously treated chronic spontaneous urticaria
Evidence Review Group Report commissioned by the NIHR HTA Programme on behalf of NICE Omalizumab for previously treated chronic spontaneous urticaria ERRATUM Replacement pages following the factual accuracy
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationTreatment for. Malaria: DHA/PQP. Science Day MMV Stakeholders Meeting. Defeating Malaria Together 1
ANewOnce-a-day Treatment for Uncomplicated Malaria: DHA/PQP Science Day MMV Stakeholders Meeting Dr. Ambrose Talisuna Former Director Global Access, MMV & Field Coordinator, African Eurartesim Registration
More informationShared Care Protocol for the Prescription of Memantine for Alzheimer s disease
Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease 1. REFERRAL CRITERIA Patients of any age that are suspected to be suffering from moderate to severe Alzheimer s disease will
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More information2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:
More informationplacebo-controlledcontrolled double-blind, blind,
Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which
More information